Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Hasan, Raghibul ^a   Sharma, Rinu ^b   Saraya, Anoop ^a   Chattopadhyay, Tushar K ^a   DattaGupta, Siddartha ^a   Walfish, Paul G ^c,d   Chauhan, Shyam S ^a   Ralhan, Ranju ^c,d  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diagnosis; Dysplasia; ESCC; Immunohistochemistry; MEKK3; Prognosis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 3;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOGENESIS; ESOPHAGUS DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MAP KINASE KINASE KINASE 3; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84891802773     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-2     Document Type: Article

References (26)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013, 132(5):1133-1145. doi: 10.1002/ijc.27711.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
3. Ryan AM, Duong M, Healy L, Ryan SA, Parekh N, Reynolds JV, Power DG. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011, 35(4):309-319.
4. Gajalakshmi V, Swaminathan R, Shanta V. An independent survey to assess completeness of registration: population based cancer registry, chennai, India. Asian Pac J Cancer Prev 2001, 2(3):179-183.
5. Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am 2012, 92(5):1077-1087.
6. Liu M, Shi X, Guo X, Yao W, Liu Y, Zhao K, Jiang GL. Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trial. Radiat Oncol 2012, 7:142.
7. Worni M, Martin J, Gloor B, Pietrobon R, D'Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg 2012, 215(5):643-651.
8. Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011, 71(5):541-555.
9. Greenwald BD, Dumot JA. Cryotherapy for Barrett's esophagus and esophageal cancer. Curr Opin Gastroenterol 2011, 27(4):363-367.
10. Hong J, Resnick M, Behar J, Wands J, DeLellis RA, Cao W. Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells. Am J Physiol Cell Physiol 2011, 301(2):C413-420.
11. Kaifi JT, Gusani NJ, Jiang Y, Mackley HB, Dye CE, Mathew A, Kimchi ET, Reed MF, Staveley-O'Carroll KF. Multidisciplinary management of early and locally advanced esophageal cancer. J Clin Gastroenterol 2011, 45(5):391-399.
12. Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, Huang PM, Lee YC. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg 2011, 253(5):918-927.
13. Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, Hsu CH, Lin CC, Cheng JC, Wang YH, Chuang TH, et al. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 2011, 18(7):2066-2073.
14. Low DE. Update on staging and surgical treatment options for esophageal cancer. J Gastrointest Surg 2011, 15(5):719-729.
15. Omloo JM, van Heijl M, Hoekstra OS, van Berge Henegouwen MI, van Lanschot JJ, Sloof GW. FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. Ann Surg Oncol 2011, 18(12):3338-3352.
16. Wang JS, Canto MI. Predicting neoplastic progression in Barrett's esophagus. Ann Gastroentol Hepatol 2011, 1(1):1-10.
17. Kumar A, Chatopadhyay T, Raziuddin M, Ralhan R. Discovery of deregulation of zinc homeostasis and its associated genes in esophageal squamous cell carcinoma using cDNA microarray. Int J Cancer 2007, 120(2):230-242.
18. Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996, 8(3):402-411.
19. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 2009, 115(17):3897-3908.
20. Deng Y, Yang J, McCarty M, Su B. MEKK3 is required for endothelium function but is not essential for tumor growth and angiogenesis. Am J Physiol Cell Physiol 2007, 293(4):C1404-1411.
21. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R. Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers 2008, 23(4):231-237.
22. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Dattagupta S, Thakar A, Chauhan SS, Siu KW. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009, 8(1):300-309.
23. Kausar T, Sharma R, Hasan MR, Tripathi SC, Saraya A, Chattopadhyay TK, Gupta SD, Ralhan R. Clinical significance of GPR56, transglutaminase 2, and NF-kappaB in esophageal squamous cell carcinoma. Cancer Invest 2010, 29(1):42-48.
24. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, et al. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. PLoS One 2010, 5(8):e11939.
25. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet 2013, 381(9864):400-412.
26. Zhang M, Zhou S, Zhang L, Ye W, Wen Q, Wang J. Role of cancer-related inflammation in esophageal cancer. Crit Rev Eukaryot Gene Expr 2013, 23(1):27-35.